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their routine clinical management. METHODS: e-STAR is an
ongoing, long-term, multinational, non-interventional observa-
tional study designed to evaluate the clinical and economic 
outcomes of patients who require a change in antipsychotic 
treatment. Data are prospectively collected over 2 years and
recorded via a secure website. Data are also recorded retrospec-
tively for a 1 year period to enable a mirror-image design in
which patients act as their own control for appropriate outcome
parameters. These include changes from baseline (time of initia-
tion of new treatment in Clinical Global Impression of Illness-
Severity (CGI-S) and Global Assessment of Functioning (GAF),
hospitalisations and adverse events. RESULTS: Presently in the
study 1107 Spanish patients have commenced treatment with
RLAI and have 6 months of follow-up. Demographics: 62.8%
male, mean (SD) age of 39.1 (11.2) years, and time since diag-
nosis 13.3 (9.7) years. Mean (SD) CGI-S score of 4.7 (1.0) at
baseline (n = 712) reﬂected marked–extremely severe illness in
57.8% and moderate illness in 32% of patients. Mean (SD) base-
line GAF score was 46.9 (16.3) n = 713), and 28.1% patients
had been hospitalised during the 6 months before RLAI. After 6
months on RLAI, mean (SD) CGI-S score had decreased to 3.9
(0.9) reﬂecting a signiﬁcant reduction from baseline and sig-
niﬁcantly fewer patients had marked-extremely severe illness
(23.7%; p < 0.001). Mean (SD) GAF score signiﬁcantly
improved to 57.2 (16.1) (p < 0.001) and signiﬁcantly fewer
patients were hospitalized (19.2%) compared with the corre-
sponding 6 month retrospective period (p < 0.001). CONCLU-
SIONS: Patients switched to RLAI during routine clinical
management are signiﬁcantly more likely to exhibit improve-
ments at six months in illness severity and functioning, and 
are less likely to require hospitalisation. Follow-up of patients is
continuing.
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OBJECTIVES: Anxiety results in physical and psychological
burdens for patients, and increased health care costs. The objec-
tive was to compare resource utilisation by patients, with and
without anxiety, in the UK. METHODS: A primary care data-
base, representative of the UK population (DIN-LINK), cover-
ing 100 practices (400 GPs), containing the records of over
800,000 registered patients was used. A cohort presenting to
General Practitioners with anxiety during the three years to
August 2005 was identiﬁed. A control cohort was identiﬁed com-
prising randomly selected patients with no history of anxiety;
this cohort was matched by age, sex, GP practice and ACORN
socio-economic classiﬁcation. Patient demographics and
resource utilisation data (including prescribed medications,
number and type of prescriptions, GP consultations, out-patient
referrals, hospital admissions, and medical certiﬁcates issued by
GPs) were reported in total, and for anxiety-related encounters.
The aggregate number of follow-up days for each cohort was
reported to facilitate comparison. RESULTS: The database iden-
tiﬁed 42,156 patients diagnosed with anxiety. There were similar
numbers of matched control subjects, with the same number of
follow-up days. The anxiety cohort each utilised the following
resources during the follow-up period compared to the matched
cohort: There were: 105% more prescriptions (n = 1,859,000) 
−26% related to anxiety; 86% more GP consultations (n =
769,000) −25% related to anxiety; 94% more outpatient refer-
rals (n = 92, 800) −23% related to anxiety; 83% more hospital
admissions (n = 12,100) −14% related to anxiety; 324% more
medical certiﬁcates issued (n = 38,000) −64% related to anxiety.
CONCLUSIONS: Patients with anxiety were prescribed many
more medications, and consumed many more primary and sec-
ondary care resources, than the matched patient cohort. The fact
that much of the additional resource use was not entirely related
to anxiety also suggests that extensive co-morbidity exists along-
side anxiety.
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OBJECTIVES: To develop a model to assess the cost-
effectiveness of a new treatment for patients with depression.
METHODS: A Markov simulation model was constructed to
evaluate standard care for depression as performed in clinical
practice compared to a new treatment for depression. Costs and
effects were estimated for time horizons of six months to ﬁve
years. A naturalistic longitudinal observational study provided
data on costs, quality of life and transition probabilities. Data
on long-term consequences of depression and mortality risks
were collected from the literature. Cost-effectiveness was quan-
tiﬁed as quality-adjusted life years (QALYs) gained from the new
treatment compared to standard care and the societal perspec-
tive was taken. Probabilistic analyses were conducted in order to
present the uncertainty in the results and sensitivity analyses
were conducted on key parameters employed in the model.
RESULTS: Compared with standard care, the new hypothetical
therapy was predicted to substantially decrease costs and was
also associated with gains in QALYs. With an improved treat-
ment effect of 50% on achieving full remission the net cost
savings were 20,000 Swedish kronor (SEK) over a follow-up time
of 5 years, given equal costs of treatments. Patients gained 0.073
QALYs over 5 years. The results are sensitive to changes in
assigned treatment effects. CONCLUSIONS: The present paper
provides a new approach for assessing the cost-effectiveness of
treatments for depression by incorporating full remission as
treatment goal and QALYs as primary outcome measure. More-
over, we show the usefulness of naturalistic real-life data on costs
and quality of life and transition probabilities when modelling
the disease over time.
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OBJECTIVES: Several new research reports coupled with state-
ments by regulatory authorities indicate that the penetration,
models for use, and acceptance of patient reported outcomes
(PRO) collected electronically (ePRO) is rapidly evolving for
clinical drug trials. METHODS: In one recent study, the Patient
Global Impression of Improvement was modiﬁed to include a
verbal recording of the subject’s health status at the beginning of
treatment. This recording was then subsequently used to orient
the subject at every subsequent rating and resulted in a 16% dif-
ference in effect size (0.0526 vs. 0.612) when compared to the
standard PGI-I. For compounds with a fast onset-of-action
proﬁle, it is critical that data be collected outside of the ofﬁce
setting. In a separate study (n = 137), patients started at higher
doses of the study drug (duloxetine) reported greater improve-
